Monopar Therapeutics (MNPR) Net Equity Issued and Repurchased (2017 - 2024)
Monopar Therapeutics (MNPR) reported Net Equity Issued and Repurchased of $1.0 million for Q4 2024, up 197.06% on a YoY basis from $339870.0 in Q1 2024, and up 100962800.0% sequentially from -$1.0 in Q2 2024.
Monopar Therapeutics (MNPR) Net Equity Issued and Repurchased (2017 - 2024) Analysis & Trends
Monopar Therapeutics (MNPR) has 6 years of Net Equity Issued and Repurchased data on file, last reported at $1.0 million in Q4 2024.
- For the quarter ending Q4 2024, Net Equity Issued and Repurchased rose 197.06% year-over-year to $1.0 million; the trailing twelve-month figure through Sep 2025 stood at $1.0 million (down 71.42% YoY), and the FY2024 full-year result was $4.2 million, up 102.6% from the prior year.
- Net Equity Issued and Repurchased rose to $1.0 million in Q4 2024, from -$1.0 in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $10.9 million in Q1 2021 to a low of -$1.0 in Q2 2024.
- A 5-year average of $2.0 million and a median of $657791.0 in 2023 frame the typical range for Net Equity Issued and Repurchased.
- Across the five-year window, Net Equity Issued and Repurchased surged 2050.47% in 2021 and slumped 100.0% in 2024, its largest moves.
- Tracing MNPR's Net Equity Issued and Repurchased over 5 years: stood at $1.0 in 2020, then surged by 1092531100.0% to $10.9 million in 2021, then slumped by 99.0% to $109337.0 in 2022, then jumped by 210.85% to $339870.0 in 2023, then jumped by 197.06% to $1.0 million in 2024.
- Business Quant data shows MNPR's Net Equity Issued and Repurchased at $1.0 million in Q4 2024, -$1.0 in Q2 2024, and $3.2 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 163.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 141.90 Mn |
| 10 | Monopar Therapeutics | 707.36 Mn | 645.53 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1.01 Mn |
| Dec 31, 2024 | 1.01 Mn |
| Jun 30, 2024 | -1.00 |
| Jun 30, 2024 | -1.00 |
| Mar 31, 2024 | 3.19 Mn |
| Mar 31, 2024 | 3.19 Mn |
| Dec 31, 2023 | 339,870.00 |
| Dec 31, 2023 | 339,870.00 |
| Sep 30, 2023 | 254,910.00 |
| Sep 30, 2023 | 254,910.00 |
| Jun 30, 2023 | 657,791.00 |
| Jun 30, 2023 | 657,791.00 |
| Mar 31, 2023 | 821,625.00 |
| Mar 31, 2023 | 821,625.00 |
| Dec 31, 2022 | 109,337.00 |
| Dec 31, 2022 | 109,337.00 |
| Mar 31, 2021 | 10.93 Mn |
| Mar 31, 2021 | 10.93 Mn |
| Dec 31, 2020 | 1.00 |
| Dec 31, 2020 | 1.00 |